Immunomedics: Company Presentation (Immunomedics) - Aug 29, 2015 - “IMMU-130 in Metastatic Colorectal Cancer”; “Promising activity in metastatic CRC previously treated with irinotecan therapy”; “Acceptable safety profile in heavily pretreated patients”; “Dose-limiting neutropenia (G3 and G4 = 10%)”; “Minimal diarrhea (G3 = 3%)”; “Best Response Results”
P1/2 data • Colorectal Cancer • Oncology
|